The clinical outcomes are complex and often involve multiple systems. Early identification and standardized clinical care are essential for improving outcomes. The diagnosis of this disease requires a combination of clinical outcomes, imaging checks, laboratory checks and pathological evaluations.
The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment plans. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat genetic metabolic diseases have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, with timely adjustments according to the changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for good comprehensive management of the prognosis of carcinoma deficiency. The platform serves a team of domestic and foreign experts in the field of genetic metabolism linked to the Chinese international medical service system, providing the following services to patients: 1. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.